Solmaz Assa

A great and highly relevant presentation at #EHRA26 by @Florienklein: Sex-specific differences in ventricular dyssynchrony at comparable QRS duration: insights from ultra-high-frequency ECG 💡 In patients with left bundle branch block, female sex was independently associated with greater ventricular dyssynchrony as assessed by ultra-high-frequency ECG @JacopoImberti @micaela_ebert @AugustoMeretta @Sharon_Man @BA_Mulder @DrAnthonyLi @veramasloo @BoldiKovacsMD @DrYanushiDW @MartinRauber3 @EHRAPresident 👇👇👇

#Europace #Epeeps 🎯Pulsed Field Ablation for the Interventional Treatment of Atrial Fibrillation. A Scientific Statement of EHRA, HRS, APHRS, LAHRS, CHRS 🔗📚 doi.org/10.1093/europa… @GiulioConteMD @FraSantoroMD @marcovitoloMD @Dominik_Linz @AndyZhangMD @DavideMei93

Heart failure with mildly reduced and preserved ejection fraction remains one of the biggest areas of unmet need in cardiovascular medicine. In our recently published review (co-authored by @jozinetm and @GianluSava) in ESC Heart Failure, we examine the established and emerging pharmacologic options for HFmrEF and HFpEF, The larger message is clear: the therapeutic landscape is finally becoming more actionable, but treatment still needs to be more deliberate, phenotype-aware, and evidence-driven. A few key takeaways: SGLT2 inhibitors now have the strongest and most consistent evidence base across EF ≥40%. Finerenone has added important momentum as a promising option for HFmrEF/HFpEF, especially as we think more seriously about cardio-kidney-metabolic biology. Phenotype-specific treatment matters. Obesity, CKD, diabetes, atrial fibrillation, and other comorbidities are not side notes in HFpEF. They are central to the disease. The obesity-HFpEF space is evolving quickly, with incretins like semaglutide and tirzepatide helping push the field toward more targeted therapeutic strategies. And importantly, there is still substantial room for progress. Ongoing studies of newer approaches, including selective MR modulation and aldosterone synthase inhibition, may help address some of the major gaps that remain. HFpEF and HFmrEF are not therapeutic dead ends like they used to feel like just 5 years ago. But they do require us to think beyond a one-size-fits-all model. doi.org/10.1093/eschf/…

🚨 IMPEDANCE-HFpEF — #ACC26 One of the most anticipated trials delivers striking results 🔑 Noninvasive lung fluid monitoring: • ↓ 81% HF hospitalizations • ↓ 65% all-cause mortality • Earlier and more frequent treatment adjustments 🧠 Detecting congestion before symptoms may change how we manage HFpEF

What an extraordinary and inspiring journey- loved your Presidential speech, Dr. Roxana Mehran. @Drroxmehran From your beginnings in Iran to becoming a global leader in interventional cardiology, your story reflects resilience, and an unwavering commitment to excellence. You have not only transformed cardiovascular research and patient care, but also paved the way for countless women and fellows who see themselves in your journey. As you step into your role as President of the American College of Cardiology, it is a proud for our entire community and #ACCWIC #ACC26

The wait is over! ⏳ At #ACC26, Dr. Edelmann is presenting the highly anticipated SPIRIT-HF trial on the main stage: Spironolactone in the Treatment of Heart Failure. Let’s set the stage as the data drops. 🧵👇 #CardioTwitter #HeartFailure

🖥️AI can play a key role in prevention, early detection & treatment of HF, driven by advancements like multimodal LLMs. But challenges like data privacy, system integration, clinician trust & fairness/bias need to be addressed. Learn more in this Review: bit.ly/4oQyuUr

The #HFA_ESC Advanced Heart Failure Course returns in 2026‼️ A unique opportunity to deepen expertise in #HeartTransplantation, mechanical circulatory support, & multidisciplinary #AdvancedHF care🫀, and to engage with global experts in the field 🤝 We look forward to welcoming you to Vienna, Austria 🇦🇹, 12–13 February 2026 Register now 🔗 esc365.escardio.org/event/2071 #HeartFailure @escardio @MajaCikes @kevin_damman @WilfriedMullens @MarcoMetra @jozinetm @h_arfsten @_antocannata @slumberbell @corneliacrm @SotiriaLiori @AmrAbdin10 @GTersalvi @GianluSava

📌 MELOS REALODED Study 📣 In 👥 w/ #AVBlock & #LVEF >40% 👉 LBB area #pacing compared to RV pacing assoc. w/ signif. ⬇️ mortality (HR=0.63) #EPeeps #CSP #LBBAP #CardioTwitter #MedTwitter @DrRoderickTung @drjohnm @HaranBurri @MdHuang @Marek_Jastrz_EP @ZacharyWhinnett @kvernooy

#MELOS RELOADED (n=3382, AVB, LVEF>40%) 📍 #LBBAP ↓ 4-yr mortality by 11.8% vs #RVP 📍LBBAP strongly linked to lower death: HR 0.53 (95% CI 0.42–0.65, p<0.001) 📍Higher risk within LBBAP group if:  – No confirmed LBB capture (HR 1.85)  – Lower % ventricular pacing  – Older age 📝 Strong support for LBBAP over RVP academic.oup.com/eurheartj/adva… @ESC_Journals

Stopping aspirin in the first few days after a PCI for acute coronary syndromes and giving Prasugrel or Ticagrelor alone did not meet meet non inferiority compared with Dual Antiplatelet Therapy for 12 months in death/MI / stroke / urgent revasc nejm.org/doi/full/10.10…

🚨ENVAD-HF: 1st prospective RCT of #SacVal in #LVAD #HM3 patients🫀 Presented by @MajaCikes 📍Less composite events (death☠️, worsening kidney function, hypotension, hyperkalemia: 7.6 vs 18.2 /100 pt-yrs 📍Safe, feasible & well tolerated 📍 Improved patient-reported outcomes (KCCQ⬆️) 📍⬇️need for additional antihypertensives SimPub at #JACCHF: jacc.org/doi/10.1016/j.… #ESCCongress #advancedHF @escardio @scottdsolomon #WCCardio

Effect of GDMT on ACM and CVD/HF Hosp in relation to baseline risk, now including #VICTOR and #DIGITHF #ESCCongress2025. What is your take on these trials in perspective of landmark #HFrEF RCTs ?

In-hospital initiation of dapagliflozin did not significantly⬇️risk of CV death or worsening HF compared w/ placebo In an accompanying meta-analysis of 3 trials, SGTL2i⬇️the early risk of CV death or worsening HF & all-cause death. ahajournals.org/doi/10.1161/CI…

#VICTOR trial (n=6105, HFrEF): #Vericiguat ⬇️ CV death (HR 0.83, p=0.02) ⬇️ all-cause death (HR 0.84, p=0.015) ⬇️ SCD (HR 0.75, p=0.042) ⬇️HF-related death (HR 0.71, p=0.016) vs placebo over ~20mo. Benefits consistent across subgroups incl. baseline #NTproBNP academic.oup.com/eurheartj/adva… #ESCCongress #EHJ @escardio @JavedButler1 @GMCRosano

Day 2 of #ESCcongress is off to a fantastic start with the hot line session🔥 1️⃣ DAPA ACT HF ❌ inhospital initiation of #dapagliflozin did not significant reduce a combined endpoint ✅ it was safe ✅ Meta-analysis with #EMPULSE and #SOLOIST does show a significant effect

#VICTOR #ESCCongress #LBCT 🫀Vericiguat in Chronic #HFrEF 🫀population:1/2 no prior HF hospitalization, excellent GDMT 🫀 Nonetheless, no significant finding of difference of Vericiguat 🆚 Placebo 🫀did ⤵️ risk of CV death

#VICTORIA & #VICTOR POOLED ANALYSIS: #LBCT #ESCCongress 2025 Presented by @JavedButler1 🫀prespecified pooled analysis of these two studies of Vericiguat 🫀 Large study: over 10,000 patients 🫀Found a 10% ⤵️ in the combined primary endpoint and also significant reduction in HFF/all cause death 🫀 Publication: @TheLancet Questions Left Behind ❓why was there lack of effect on HF hospitalizations in VICTOR but many in VICTORIA: with expanded endpoint then there was a treatment effect ❓why more effect on CV death rather than HF hospitalizations 🏥

DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure #LBCT #ESCCongress #WCCongress 2025 🫀1:1 RCT of Dapa 🆚 Placebo 🫀34% female, 19% Black 🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of LVDeath/worsening HF 🫀 Non significant findings could be due to short follow up (60d) and also less events in this population

#ESCcongress #SnackableScience ⬇️